➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Baxter
Boehringer Ingelheim
AstraZeneca
Harvard Business School

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

ZANAFLEX Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Zanaflex patents expire, and when can generic versions of Zanaflex launch?

Zanaflex is a drug marketed by Covis and is included in two NDAs.

The generic ingredient in ZANAFLEX is tizanidine hydrochloride. There are eleven drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the tizanidine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zanaflex

A generic version of ZANAFLEX was approved as tizanidine hydrochloride by CASI PHARMS INC on June 27th, 2002.

  Try it Free

Drug patent expirations by year for ZANAFLEX
Drug Prices for ZANAFLEX

See drug prices for ZANAFLEX

Recent Clinical Trials for ZANAFLEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Center for Advancing Translational Science (NCATS)Phase 2
University of California, San DiegoPhase 2
Acorda TherapeuticsPhase 2

See all ZANAFLEX clinical trials

Pharmacology for ZANAFLEX
Paragraph IV (Patent) Challenges for ZANAFLEX
Tradename Dosage Ingredient NDA Submissiondate
ZANAFLEX CAPSULE;ORAL tizanidine hydrochloride 021447 2007-08-10

US Patents and Regulatory Information for ZANAFLEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-001 Aug 29, 2002 AB RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Covis ZANAFLEX tizanidine hydrochloride TABLET;ORAL 020397-002 Feb 4, 2000 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Covis ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-002 Aug 29, 2002 AB RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Covis ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-003 Aug 29, 2002 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Covis ZANAFLEX tizanidine hydrochloride TABLET;ORAL 020397-001 Nov 27, 1996 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Baxter
Boehringer Ingelheim
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.